SuperworthRani Therapeutics shares outstanding RANI
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 187.2M
- On a year earlier
- +412.2%
- more shares
Rani Therapeutics had 187.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 412.2% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 147.1M | +350% |
| FY2024 | 32.7M | +26% |
| FY2023 | 25.9M | +4% |
| FY2022 | 24.9M | +26% |
| FY2021 | 19.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 187.2M | +412% | |
| Q1 FY26 | 180M | +438% | |
| Q4 FY25 | 147.1M | +350% | |
| Q3 FY25 | 46.4M | +61% | |
| Q2 FY25 | 36.5M | +39% | |
| Q1 FY25 | 33.4M | +28% | |
| Q4 FY24 | 32.7M | +26% | |
| Q3 FY24 | 28.8M | +13% | |
| Q2 FY24 | 26.3M | +4% | |
| Q1 FY24 | 26M | +3% | |
| Q4 FY23 | 25.9M | +4% | |
| Q3 FY23 | 25.6M | +4% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Rani Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.